Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/9150Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Papathanasiou, A. I. | en |
| dc.contributor.author | Lourida, E. S. | en |
| dc.contributor.author | Tsironis, L. D. | en |
| dc.contributor.author | Goudevenos, J. A. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.date.accessioned | 2015-11-24T16:47:12Z | - |
| dc.date.available | 2015-11-24T16:47:12Z | - |
| dc.identifier.issn | 0021-9150 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/9150 | - |
| dc.rights | Default Licence | - |
| dc.subject | oxidation | en |
| dc.subject | atherosclerosis | en |
| dc.subject | lipoproteins | en |
| dc.subject | atorvastain | en |
| dc.subject | autoantibodies | en |
| dc.subject | lipoprotein-associated phospholipase a(2) | en |
| dc.subject | paf-acetylhydrolase | en |
| dc.subject | low-density-lipoprotein | en |
| dc.subject | activating factor-acetylhydrolase | en |
| dc.subject | artery-disease | en |
| dc.subject | paf-acetylhydrolase | en |
| dc.subject | degrading acetylhydrolase | en |
| dc.subject | oxidative modification | en |
| dc.subject | phospholipids | en |
| dc.subject | hypercholesterolemia | en |
| dc.subject | atherosclerosis | en |
| dc.subject | antioxidants | en |
| dc.title | Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes - Role of the lipoprotein-associated phospholipase A(2) and the effect of atorvastatin treatment | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | DOI 10.1016/j.atherosclerosis.2006.10.033 | - |
| heal.identifier.secondary | <Go to ISI>://000253341500037 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0021915006006708/1-s2.0-S0021915006006708-main.pdf?_tid=906fa7d02083fe92597e539ce538a431&acdnat=1333111724_def0539fea8ea48a79b9a803c0d944bf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | Oxidized low-density lipoprotein (oxLDL) is immunogenic while oxidized phospholipids (oxPL) formed on oxLDL and lysophosphatidylcholine (lyso-PC) generated during LDL oxidation through the hydrolysis of oxPL by the lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), significantly contribute to oxLDL immunogenicity. We determined the autoantibody titers against various forms of mildly oxLDL in patients with acute coronary syndromes without persistent elevation of the ST segment (NSTE-ACS) and with undetectable serum levels of lipoprotein (a). Moreover, the effect of early atorvastatin administration on these autoantibody titers was evaluated. From the 133 consecutive NSTE-ACS patients, 55 were eligible for the study. Thirty-four received atorvastatin (group A), whereas 21 did not received any hypolipdemic therapy (group B). Two forms of copper-oxidized LDL were prepared at the end of propagation or decomposition phase (oxLDL(P) or oxLDL(D), respectively). Similar types of oxLDL were prepared after previous inactivation of the endogenous Lp-PLA(2) [oxLDL(-)]. In group B, autoantibody titers of IgG class against oxLDL(P) and oxLDL(D) were elevated at 1 month of follow-up to reach the baseline values 3 months afterwards. By contrast the titers against oxLDL(-)(P) and oxLDL(-)(D) increased at 1 month of follow-up and remained elevated for up to 6 months of follow-up. Atorvastatin treatment prevented the elevation of autoantibody titers against all forms of oxidized LDL. We conclude that a short-term immune response against oxLDL(P) and oxLDLD (enriched in lyso-PC) and a chronic immune response against oxLDL(-)(P) and oxLDL(-)(D) (enriched in oxPL) are observed after an NSTE-ACS, suggesting an important role of the LDL-associated Lp-PLA(2) in modulating these immune responses. Early atorvastatin treatment prevents both immune responses; however, the clinical significance of this effect remains to be established. (C) 2006 Elsevier Ireland Ltd. All rights reserved. | en |
| heal.journalName | Atherosclerosis | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Papathanasiou-2008-Short- and long-term.pdf | 183.91 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
